We would love to hear your thoughts about our site and services, please take our survey here.
Any further fall must be viewed as a buying opportunity as this company has shown that it can make money. Waiting game indeed...
A look at the shareholders suggest quite a bit held by management and other investors. When this SP moves it will move quickly on news. https://wqbi611kuap2slk9j2m1xr7a-wpengine.netdna-ssl.com/Significant-Shareholders-02-Dec2019.pdf
Others suggest strong buy as well: https://uk.tradingview.com/symbols/LSE-EUA/
Gold price is rising rapidly....one way up for this stock https://www.gold.co.uk/gold-price/
Some folks suggest strong buy...... https://uk.tradingview.com/symbols/LSE-GGP/
Just curious whether anyone has a link to any revised balance sheet for this new entity - it would be appreciated if shared. I have been concerned about what the new entity looks like from a fundamentals approach as I have seen posts suggesting that the acquired company will bring in needed revenue. I would like to see the evidence of that. The horse has already bolted but it would be good to know if we are left with a donkey. I had a look at the Adept website and I have to say that I am even more concerned that a tech firm has an outdated financial calendar page dating back to September 2015 as of this post. Take a look: https://www.adept4.co.uk/investors/financial-calendar
Good time to use any spare cash. Should now pay off going through Thursday! DYOR.
Sorry please ignore....misread dates
Based on recent RNS the stock price should soon revert to placing price or lower as dilution is coming IMHO. They are seeking to raise funds.....
Last 3 days have been red all over the shop but I am confident next week will be different.....GLA
One good platform is ETX. Focus should be on American market and commodities which pays better IMHO. Big problems are sleepless nights/weekends and a very dangerous play on your capital.
draft on a lighter note I see that views of this video has almost doubled since you shared the link. Well done. Pity management did not have a more appropriate background - the orchid should at least be in bloom! On a more serious note, I too am concerned about whether this company is putting things in place to move forward. I expect full transparency as it relates to approvals and licences as this materially affects investment decisions.
JC the question was asked why the price isn't moving based on the news today. I am not in a position to offer suggestions about sales except to say that if we seek the interest of the big guns we need more certainty of sales. I am not in disagreement with you. The horizon for Institution Investors is short as they also must show a return on their investment. Part of management's job must be to show that the promise is not an ongoing promise but one which will begin to generate cash.
For sure that equates to forseeable revenue which will cause an increase....I also believe in fundamentals....time to actually start booking some revenue....it does help Institutional Investors to justify their decisions to invest. I am in for the wait as I have digested the technical information and love discovery stocks...
Market requires actual revenue for GGP price to start moving up. Very good prospect and willing to wait...
https://www.ig.com/uk/trading-strategies/-buy-the-rumour--sell-the-news--explained-190319#information-banner-dismiss
Seems like some have interpreted the news differently and sold. Will continue to add if this keeps messing about.
I agree with the king. At 50p and a modest p/e of 5, earnings necessary would need to be a low and achievable percentage of the US market size. This is company is going places once sales contracts are in place. DYOR.
One sure way to assist this enterprise is to subscribe to its channel - currently a very small number! They would do better with a sharper PR effort, in particular social media.
I agree BX.....I'm holding... Also this is taken from an article earlier this year: "The other factor to watch is competition from another drug, Sublocade, also launched by Indivior. The company launched this drug in the first quarter of calendar year 2018. The difference is that Sublocase is a long acting drug, the injection just needs to be taken once a month versus Suboxone that is a daily dose." Source: https://www.cnbctv18.com/healthcare/the-suboxone-opportunity-for-dr-reddys-135871.htm